Conference Coverage

Vemurafenib After Ipilimumab Linked to Rash

Publish date: August 27, 2012

 

AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Dr. Harding disclosed no relevant conflicts of interest. Dr. Sznol disclosed that he is a consultant to Abbott Laboratories, Anaeropharma, BioVex, Bristol-Myers Squibb, Genesis Biopharma, Genzyme, and Prometheus; receives honoraria from Prometheus; and receives research funding from Bristol-Myers Squibb.

Pages

Recommended Reading

Invasive SCC Rates Doubled in Last 20 Years
MDedge Hematology and Oncology
Washington Post Blasts Proliferation of ESAs for Anemia
MDedge Hematology and Oncology
Expert: Reclaim Radiation for Skin Cancer
MDedge Hematology and Oncology
Labs Find Evidence of Cancer Stem Cells
MDedge Hematology and Oncology
Isotretinoin Quells EGFR Inhibitor-Related Rash
MDedge Hematology and Oncology
Blood Pressure Meds Linked to Lip Cancer
MDedge Hematology and Oncology
Pregnancy-Related Cancers: Rise Is Largely Unrelated to Delayed Childbearing
MDedge Hematology and Oncology
Melanoma Sinks Hook Into Coral Reef Trout
MDedge Hematology and Oncology
KIT Inhibition Promising for Select Few
MDedge Hematology and Oncology
Kaposi's Sarcoma Makes Unwelcome Return
MDedge Hematology and Oncology